Application of blood serum sST2 in dilated cardiomyopathy prognosis

A dilated cardiomyopathy, pediatric technology, applied in the fields of treatment and prognosis, disease diagnosis, and biotechnology, can solve the problem of unknown predictive value of sST2 in children with dilated cardiomyopathy.

Active Publication Date: 2018-12-11
BEIJING INST OF HEART LUNG & BLOOD VESSEL DISEASES
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although some small cross-sectional studies have described the level and characteristics of sST2 in normal children (Caselli C, et al. Biomark Med. 2016), the predictive value of sST2 in children with dilated cardiomyopathy is unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of blood serum sST2 in dilated cardiomyopathy prognosis
  • Application of blood serum sST2 in dilated cardiomyopathy prognosis
  • Application of blood serum sST2 in dilated cardiomyopathy prognosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Example 1: Correlation between the level of serum sST2 and adverse events in children with dilated cardiomyopathy (DCM)

[0066] 1. Patient enrollment conditions and follow-up strategy

[0067] figure 1 A flow diagram of the study of the present invention is shown. The AOCC Study (Chinese Cardiomyopathy Diagnosis and Prognosis Study) is a double-center, observational, prospective, comprehensive, multi-omics study. All children (<18 years old) were treated at Beijing Anzhen Hospital and Fuwai Hospital from September 2015 to March 2017.

[0068] Dilated cardiomyopathy and heart failure were diagnosed and identified by at least 3 experienced cardiologists. Dilated cardiomyopathy is defined as the presence of at least 2 of the following criteria: (1) symptomatic heart failure; (2) left ventricular or biventricular systolic dysfunction; (3) ventricular dysfunction not explained by abnormal loading or coronary artery disease expansion. Systolic dysfunction was defined a...

Embodiment 2

[0095] Example 2: Serum sST2 levels can improve the predictive ability of serum BNP to predict the occurrence of adverse events in children with DCM

[0096] It has been reported in the literature that BNP is an independent predictor of adverse events in children with DCM (Suthar D, etal. Pediatr Cardiol. 2018). The present invention further verifies whether sST2 can improve the predictive ability of BNP.

[0097] For the risk prediction of recent adverse events, adding serum sST2 levels to the analysis of BNP to predict the risk of adverse events in children with DCM resulted in a C-statistic from 0.697 (95% CI, 0.541-0.852; P< 0.05) increased to 0.812 (95% CI, 0.697-0.939; P<0.05); NRI was 0.204 (95% CI, 0.048-0.375), while IDI also showed a corresponding improvement, see Table 4 for details.

[0098] For the risk prediction of long-term adverse events, increasing the serum sST2 level to BNP to predict the risk of adverse events in children with DCM, the C-statistic (C-stat...

Embodiment 3

[0106] Example 3: Continuous monitoring of serum sST2 levels can be used to monitor the course of disease in children with DCM

[0107] Previous studies have found that the increase in the level of sST2 precedes the occurrence of adverse events, suggesting that sST2 may be used for prognosis and detection of disease in clinical practice (van Vark LC et al. J Am Coll Cardiol. 2017). In order to avoid the confounding offset caused by children's development to the greatest extent, the present invention uses a nested case-control (Sadek AA, et al. Electron Physician. 2017) to evaluate the predictive value of repeated measurement of serum sST2.

[0108] In addition to the 7 children with recent adverse events, 21 children with DCM had adverse events (defined as late events) after 6 months of enrollment, including 19 children at 3 months and 6 months. Serum samples were collected during the follow-up visits; 19 children with consistent gender, age and anti-DCM treatment intervention...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a novel use of a substance for detecting content of soluble ST2 (sST2) protein and a novel use of taking the soluble ST2 (sST2) as a blood serum marker. The sST2 which is takenas the blood serum marker can be independently applied to risk stratification of a child patient with dilated cardiomyopathy (DCM) and predication of an adverse event (all-cause mortality/ heart transplantation/ rehospitalization as a result of congestive heart failure); meanwhile, the sST2 which is taken as the blood serum marker can improve predication ability of a conventional marker-BNP, can be used for monitoring DCM child patient disease progression and is not affected by a renal function and BMI. The application provides scientific basis for monitoring risk stratification, prognosis anddisease progression of the patient with dilated cardiomyopathy, greatly and positively intervenes a decision opportunity clinically before the adverse event occurs, makes up the research and clinicalapplication blank of the medical industry, and has great potential and value of clinical and market application.

Description

technical field [0001] The invention belongs to the technical fields of biotechnology, disease diagnosis, treatment and prognosis, and specifically relates to the application of serum sST2 in the prognosis of children with dilated cardiomyopathy. Background technique [0002] Dilated cardiomyopathy (Dilated Cardiomyopathy, DCM) is mainly characterized by left ventricular enlargement and abnormal systolic function, and the prevalence rate in minors is about 0.57-1.13 / 100000 (Lipshultz SE, et al.N Engl JMed.2003) ( Towbin JA, et al. JAMA, 2006), which is one of the most common causes of congestive heart failure in children and the leading cause of heart transplantation in children (Lipshultz SE, et al. Future Cardiol. 2013). The prognosis of dilated cardiomyopathy is generally poor. Registry studies in the United States, Australia, and Europe have found that the five-year survival rate of children with DCM is 25%-40% (Lee TM, et al. Circ Res. 2017). [0003] Identifying "high...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCG01N33/68G01N2800/325
Inventor 杜杰尤宏钊焦萌王媛李玉琳姜文溪乔博康
Owner BEIJING INST OF HEART LUNG & BLOOD VESSEL DISEASES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap